Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02638909 · ClinicalTrials.gov registry record · Phase 2
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase 2 study, sponsored by Criterium.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02638909: Clinical Trial Phase 2 study, sponsored by Criterium.
NCT02638909 is a Phase 2 study that was terminated before completion, run by Criterium. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02638909, a Phase 2 study, was terminated before completion, sponsored by Criterium.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The available data indicate that Ceritinib has substantial anti-tumor activity in patients with anaplastic lymphoma kinase (ALK) and ROS1 rearranged non-small cell lung cancer (NSCLC). This trial will investigate the potential of Ceritinib in patients with advanced gastrointestinal malignancies with ALK and ROA1 rearrangement, and for whom there is no available therapeutic option.
Interventions
- DRUG ceritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-03-29 |
| Phase | Phase 2 |
Why NCT02638909 stopped before completion
NCT02638909 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which ceritinib is the first listed.
NCT02638909 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02638909 about?
NCT02638909 is a clinical study titled "Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies". The available data indicate that Ceritinib has substantial anti-tumor activity in patients with anaplastic lymphoma kinase (ALK) and ROS1 rearranged non-small cell lung cancer (NSCLC). This trial will investigate the potential of Ceritinib in patients with advanced gastrointestinal malignancies with...
What is the current status of trial NCT02638909?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2015-12. Estimated completion is 2018-03-29.
What interventions are being tested in trial NCT02638909?
The interventions under investigation include: ceritinib (DRUG).
Who is sponsoring clinical trial NCT02638909?
This trial is sponsored by Criterium, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02638909's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia